| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Apoptosis | 15 | 2010 | 352 | 1.060 |
Why?
|
| Prostatic Neoplasms | 14 | 2010 | 457 | 0.920 |
Why?
|
| Membrane Glycoproteins | 10 | 2005 | 107 | 0.770 |
Why?
|
| Tumor Necrosis Factor-alpha | 10 | 2005 | 211 | 0.730 |
Why?
|
| Hydroxamic Acids | 3 | 2006 | 20 | 0.610 |
Why?
|
| Carrier Proteins | 5 | 2006 | 136 | 0.540 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 4 | 1999 | 16 | 0.520 |
Why?
|
| Apoptosis Regulatory Proteins | 10 | 2005 | 43 | 0.420 |
Why?
|
| Histone Deacetylase Inhibitors | 3 | 2006 | 21 | 0.400 |
Why?
|
| Caspases | 11 | 2010 | 42 | 0.370 |
Why?
|
| Enzyme Inhibitors | 6 | 2007 | 168 | 0.360 |
Why?
|
| TNF-Related Apoptosis-Inducing Ligand | 13 | 2010 | 23 | 0.350 |
Why?
|
| Mutation | 6 | 2014 | 475 | 0.350 |
Why?
|
| Tumor Suppressor Protein p53 | 7 | 2014 | 78 | 0.340 |
Why?
|
| beta-Thalassemia | 5 | 1994 | 11 | 0.310 |
Why?
|
| Caspase 2 | 2 | 2006 | 2 | 0.300 |
Why?
|
| Adenoviruses, Simian | 3 | 1996 | 3 | 0.270 |
Why?
|
| Adenovirus E1A Proteins | 3 | 1996 | 10 | 0.250 |
Why?
|
| Chromosomes, Human, Pair 22 | 3 | 1999 | 20 | 0.240 |
Why?
|
| Chromosomes, Human, Pair 9 | 3 | 1999 | 16 | 0.240 |
Why?
|
| Translocation, Genetic | 3 | 1999 | 20 | 0.240 |
Why?
|
| Oncogenes | 2 | 1994 | 8 | 0.240 |
Why?
|
| Cell Line, Tumor | 8 | 2014 | 692 | 0.220 |
Why?
|
| Fusion Proteins, bcr-abl | 2 | 1999 | 10 | 0.210 |
Why?
|
| Mitochondria | 7 | 2006 | 181 | 0.210 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 6 | 2004 | 37 | 0.200 |
Why?
|
| Receptors, Androgen | 5 | 2010 | 44 | 0.200 |
Why?
|
| Base Sequence | 13 | 2005 | 255 | 0.190 |
Why?
|
| Pancreatic Neoplasms | 2 | 2014 | 133 | 0.190 |
Why?
|
| Polymorphism, Genetic | 4 | 1995 | 200 | 0.190 |
Why?
|
| Tumor Cells, Cultured | 9 | 2010 | 168 | 0.180 |
Why?
|
| Humans | 35 | 2014 | 29614 | 0.180 |
Why?
|
| Molecular Sequence Data | 12 | 2002 | 366 | 0.170 |
Why?
|
| Codon | 3 | 1995 | 10 | 0.170 |
Why?
|
| Drug Resistance, Multiple | 1 | 1999 | 9 | 0.170 |
Why?
|
| Signal Transduction | 5 | 2010 | 674 | 0.160 |
Why?
|
| DNA | 4 | 1997 | 209 | 0.160 |
Why?
|
| Hypereosinophilic Syndrome | 1 | 1998 | 3 | 0.160 |
Why?
|
| DNA, Viral | 3 | 1996 | 50 | 0.150 |
Why?
|
| Receptors, Tumor Necrosis Factor | 5 | 2007 | 50 | 0.150 |
Why?
|
| Adaptor Proteins, Signal Transducing | 3 | 2002 | 68 | 0.150 |
Why?
|
| Male | 20 | 2014 | 18037 | 0.150 |
Why?
|
| Cell Survival | 4 | 2010 | 278 | 0.150 |
Why?
|
| Androgens | 3 | 2007 | 25 | 0.140 |
Why?
|
| Granulocyte-Macrophage Colony-Stimulating Factor | 1 | 1995 | 25 | 0.130 |
Why?
|
| Proto-Oncogene Proteins c-akt | 4 | 2010 | 73 | 0.130 |
Why?
|
| Caspase 8 | 5 | 2007 | 14 | 0.130 |
Why?
|
| Adenovirus E1B Proteins | 2 | 1996 | 19 | 0.130 |
Why?
|
| Polymerase Chain Reaction | 12 | 2002 | 185 | 0.130 |
Why?
|
| rab GTP-Binding Proteins | 1 | 2014 | 4 | 0.130 |
Why?
|
| G1 Phase | 1 | 2014 | 11 | 0.120 |
Why?
|
| Retinoblastoma Protein | 1 | 2014 | 11 | 0.120 |
Why?
|
| S Phase | 1 | 2014 | 14 | 0.120 |
Why?
|
| Oncogene Proteins | 1 | 2014 | 6 | 0.120 |
Why?
|
| Cell Proliferation | 2 | 2014 | 576 | 0.120 |
Why?
|
| Neuroendocrine Tumors | 1 | 2014 | 21 | 0.120 |
Why?
|
| Genes, Viral | 1 | 1994 | 7 | 0.120 |
Why?
|
| Haplotypes | 1 | 1994 | 221 | 0.120 |
Why?
|
| Enzyme Activation | 4 | 2006 | 130 | 0.120 |
Why?
|
| Transfection | 4 | 2010 | 196 | 0.110 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 1994 | 58 | 0.110 |
Why?
|
| Gene Expression Regulation, Neoplastic | 3 | 2004 | 252 | 0.110 |
Why?
|
| Caspase 9 | 4 | 2006 | 11 | 0.110 |
Why?
|
| Benzylamines | 2 | 2010 | 5 | 0.110 |
Why?
|
| Sulfonamides | 2 | 2010 | 67 | 0.110 |
Why?
|
| RNA, Small Interfering | 3 | 2008 | 112 | 0.100 |
Why?
|
| Death Domain Receptor Signaling Adaptor Proteins | 3 | 2006 | 3 | 0.100 |
Why?
|
| Globins | 5 | 1993 | 8 | 0.100 |
Why?
|
| Erythrocyte Membrane | 1 | 1990 | 2 | 0.090 |
Why?
|
| Neuromuscular Diseases | 1 | 1990 | 14 | 0.090 |
Why?
|
| Disease Models, Animal | 1 | 2014 | 984 | 0.090 |
Why?
|
| Factor IX | 3 | 1995 | 11 | 0.090 |
Why?
|
| Ascorbic Acid | 1 | 2010 | 22 | 0.090 |
Why?
|
| Cell Death | 2 | 2006 | 74 | 0.080 |
Why?
|
| Membrane Proteins | 1 | 1990 | 257 | 0.080 |
Why?
|
| Genetics, Population | 2 | 2002 | 32 | 0.080 |
Why?
|
| Genes, abl | 2 | 1999 | 3 | 0.080 |
Why?
|
| Animals | 8 | 2014 | 7341 | 0.080 |
Why?
|
| Oxidative Stress | 1 | 2010 | 224 | 0.080 |
Why?
|
| Neoplasms | 1 | 2014 | 628 | 0.080 |
Why?
|
| Ligands | 2 | 2005 | 83 | 0.080 |
Why?
|
| Doxorubicin | 4 | 2010 | 60 | 0.080 |
Why?
|
| Antibiotics, Antineoplastic | 4 | 2010 | 66 | 0.080 |
Why?
|
| NF-kappa B | 2 | 2004 | 77 | 0.070 |
Why?
|
| DNA, Mitochondrial | 2 | 2004 | 30 | 0.070 |
Why?
|
| Models, Biological | 2 | 2005 | 375 | 0.070 |
Why?
|
| Blotting, Western | 5 | 2010 | 286 | 0.070 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 3 | 2007 | 251 | 0.070 |
Why?
|
| Calcium-Calmodulin-Dependent Protein Kinase Type 2 | 1 | 2007 | 6 | 0.070 |
Why?
|
| Adenocarcinoma | 1 | 2010 | 302 | 0.070 |
Why?
|
| CRADD Signaling Adaptor Protein | 1 | 2006 | 1 | 0.070 |
Why?
|
| Cytochromes c | 1 | 2006 | 4 | 0.070 |
Why?
|
| Azerbaijan | 4 | 1994 | 4 | 0.070 |
Why?
|
| MicroRNAs | 1 | 2008 | 174 | 0.070 |
Why?
|
| Phosphorylation | 2 | 2003 | 229 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 198 | 0.060 |
Why?
|
| Mice | 3 | 2010 | 2388 | 0.060 |
Why?
|
| Tosylphenylalanyl Chloromethyl Ketone | 1 | 2004 | 1 | 0.060 |
Why?
|
| Alkylating Agents | 1 | 2004 | 5 | 0.060 |
Why?
|
| Androstadienes | 4 | 2007 | 21 | 0.060 |
Why?
|
| Polymorphism, Restriction Fragment Length | 3 | 1993 | 12 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2007 | 681 | 0.060 |
Why?
|
| Luciferases | 3 | 2010 | 30 | 0.060 |
Why?
|
| RNA, Messenger | 3 | 2006 | 523 | 0.060 |
Why?
|
| Fas-Associated Death Domain Protein | 4 | 2007 | 4 | 0.060 |
Why?
|
| Point Mutation | 2 | 1994 | 25 | 0.060 |
Why?
|
| bcl-Associated Death Protein | 1 | 2003 | 7 | 0.060 |
Why?
|
| Cytosol | 1 | 2003 | 26 | 0.060 |
Why?
|
| Caspase 3 | 1 | 2003 | 31 | 0.060 |
Why?
|
| Prenatal Diagnosis | 2 | 1993 | 21 | 0.060 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2010 | 80 | 0.050 |
Why?
|
| Sciuridae | 1 | 2002 | 3 | 0.050 |
Why?
|
| Chimera | 1 | 2002 | 9 | 0.050 |
Why?
|
| Maleimides | 1 | 2002 | 5 | 0.050 |
Why?
|
| Hygromycin B | 1 | 2002 | 1 | 0.050 |
Why?
|
| Cinnamates | 1 | 2002 | 4 | 0.050 |
Why?
|
| Indoles | 1 | 2002 | 59 | 0.050 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2002 | 5 | 0.050 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 73 | 0.050 |
Why?
|
| Transcription, Genetic | 1 | 2002 | 138 | 0.050 |
Why?
|
| Genes, MDR | 1 | 1999 | 1 | 0.040 |
Why?
|
| Immunophenotyping | 1 | 1999 | 50 | 0.040 |
Why?
|
| Drug Synergism | 2 | 2010 | 69 | 0.040 |
Why?
|
| Ilium | 1 | 1998 | 14 | 0.040 |
Why?
|
| Autopsy | 1 | 1998 | 38 | 0.040 |
Why?
|
| Fatal Outcome | 1 | 1998 | 79 | 0.040 |
Why?
|
| Spleen | 1 | 1998 | 83 | 0.040 |
Why?
|
| Hedgehogs | 1 | 1997 | 1 | 0.040 |
Why?
|
| DNA Primers | 3 | 2005 | 90 | 0.040 |
Why?
|
| Fibroblasts | 2 | 1996 | 105 | 0.040 |
Why?
|
| Biopsy | 1 | 1998 | 243 | 0.040 |
Why?
|
| Immunoprecipitation | 2 | 2007 | 34 | 0.040 |
Why?
|
| Survival Rate | 1 | 1999 | 797 | 0.030 |
Why?
|
| Sequence Deletion | 2 | 1993 | 38 | 0.030 |
Why?
|
| Chronic Disease | 1 | 1998 | 376 | 0.030 |
Why?
|
| Virus Integration | 1 | 1996 | 4 | 0.030 |
Why?
|
| Solubility | 1 | 1995 | 39 | 0.030 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 275 | 0.030 |
Why?
|
| Water | 1 | 1995 | 53 | 0.030 |
Why?
|
| Female | 6 | 2014 | 18414 | 0.030 |
Why?
|
| DNA, Satellite | 1 | 1995 | 2 | 0.030 |
Why?
|
| Reference Values | 1 | 1995 | 227 | 0.030 |
Why?
|
| Adult | 3 | 1998 | 8535 | 0.030 |
Why?
|
| Receptors, TNF-Related Apoptosis-Inducing Ligand | 2 | 2007 | 8 | 0.030 |
Why?
|
| Mitosis | 1 | 2014 | 23 | 0.030 |
Why?
|
| Prognosis | 1 | 1999 | 1373 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 2 | 2010 | 643 | 0.030 |
Why?
|
| Genes, ras | 1 | 2014 | 27 | 0.030 |
Why?
|
| Liver | 1 | 1998 | 465 | 0.030 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 2 | 2006 | 8 | 0.030 |
Why?
|
| Hemophilia B | 1 | 1994 | 6 | 0.030 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2007 | 92 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1994 | 14 | 0.030 |
Why?
|
| Blotting, Southern | 1 | 1994 | 22 | 0.030 |
Why?
|
| Sequence Homology, Nucleic Acid | 1 | 1994 | 19 | 0.030 |
Why?
|
| Swine | 1 | 2014 | 204 | 0.030 |
Why?
|
| Rats | 2 | 1996 | 1609 | 0.030 |
Why?
|
| Frameshift Mutation | 1 | 1993 | 5 | 0.030 |
Why?
|
| Base Composition | 1 | 1992 | 9 | 0.030 |
Why?
|
| Restriction Mapping | 3 | 2002 | 13 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 1993 | 68 | 0.030 |
Why?
|
| Gene Deletion | 1 | 1992 | 65 | 0.030 |
Why?
|
| Alleles | 1 | 1993 | 252 | 0.030 |
Why?
|
| Proto-Oncogene Proteins | 2 | 2002 | 92 | 0.020 |
Why?
|
| Thalassemia | 1 | 1990 | 1 | 0.020 |
Why?
|
| DNA Probes | 1 | 1990 | 18 | 0.020 |
Why?
|
| Spectrophotometry | 1 | 1990 | 22 | 0.020 |
Why?
|
| Spectrometry, Fluorescence | 1 | 1990 | 25 | 0.020 |
Why?
|
| Membrane Potential, Mitochondrial | 1 | 2010 | 17 | 0.020 |
Why?
|
| Russia | 2 | 2002 | 4 | 0.020 |
Why?
|
| Electrophoretic Mobility Shift Assay | 1 | 2010 | 18 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 47 | 0.020 |
Why?
|
| Cytotoxins | 1 | 2010 | 12 | 0.020 |
Why?
|
| Species Specificity | 2 | 2002 | 87 | 0.020 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2010 | 114 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2010 | 173 | 0.020 |
Why?
|
| Hydrogen Peroxide | 1 | 2010 | 82 | 0.020 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2014 | 875 | 0.020 |
Why?
|
| Child | 2 | 1993 | 2234 | 0.020 |
Why?
|
| Mice, Nude | 1 | 2010 | 277 | 0.020 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2014 | 1229 | 0.020 |
Why?
|
| Cells, Cultured | 1 | 2010 | 803 | 0.020 |
Why?
|
| CASP8 and FADD-Like Apoptosis Regulating Protein | 1 | 2007 | 2 | 0.020 |
Why?
|
| Cycloheximide | 1 | 2007 | 8 | 0.020 |
Why?
|
| Thapsigargin | 1 | 2007 | 8 | 0.020 |
Why?
|
| Prostate-Specific Antigen | 1 | 2007 | 62 | 0.020 |
Why?
|
| Isoenzymes | 1 | 2007 | 64 | 0.020 |
Why?
|
| Cysteine Proteinase Inhibitors | 1 | 2006 | 5 | 0.020 |
Why?
|
| Leupeptins | 1 | 2006 | 5 | 0.020 |
Why?
|
| Immunosuppressive Agents | 1 | 2007 | 168 | 0.020 |
Why?
|
| Prostate | 1 | 2006 | 69 | 0.020 |
Why?
|
| Promoter Regions, Genetic | 1 | 2006 | 214 | 0.020 |
Why?
|
| NF-kappa B p50 Subunit | 1 | 2004 | 5 | 0.020 |
Why?
|
| Transcription Factor RelA | 1 | 2004 | 23 | 0.020 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 19 | 0.020 |
Why?
|
| RNA | 1 | 2004 | 89 | 0.010 |
Why?
|
| Time Factors | 1 | 2008 | 2014 | 0.010 |
Why?
|
| Genetic Markers | 2 | 1993 | 124 | 0.010 |
Why?
|
| Founder Effect | 1 | 2002 | 5 | 0.010 |
Why?
|
| Random Amplified Polymorphic DNA Technique | 1 | 2002 | 3 | 0.010 |
Why?
|
| Pseudogenes | 1 | 2002 | 5 | 0.010 |
Why?
|
| Dactinomycin | 1 | 2002 | 11 | 0.010 |
Why?
|
| Blotting, Northern | 1 | 2002 | 27 | 0.010 |
Why?
|
| Protein Synthesis Inhibitors | 1 | 2002 | 13 | 0.010 |
Why?
|
| Cyclins | 1 | 2002 | 6 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-mdm2 | 1 | 2002 | 9 | 0.010 |
Why?
|
| Pedigree | 2 | 1994 | 135 | 0.010 |
Why?
|
| Peptide Hydrolases | 1 | 2002 | 16 | 0.010 |
Why?
|
| Culture Media | 1 | 2002 | 40 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2002 | 82 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2002 | 37 | 0.010 |
Why?
|
| Precipitin Tests | 1 | 2002 | 13 | 0.010 |
Why?
|
| Genes, Dominant | 1 | 2002 | 27 | 0.010 |
Why?
|
| Cytochrome c Group | 1 | 2001 | 2 | 0.010 |
Why?
|
| Enzyme Induction | 1 | 2001 | 32 | 0.010 |
Why?
|
| Proteins | 1 | 2002 | 141 | 0.010 |
Why?
|
| Pregnancy | 2 | 1993 | 827 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2004 | 548 | 0.010 |
Why?
|
| Arctic Regions | 1 | 1997 | 1 | 0.010 |
Why?
|
| Cell Transformation, Viral | 1 | 1996 | 6 | 0.010 |
Why?
|
| Repetitive Sequences, Nucleic Acid | 1 | 1995 | 7 | 0.010 |
Why?
|
| X Chromosome | 1 | 1995 | 25 | 0.010 |
Why?
|
| Introns | 1 | 1995 | 40 | 0.010 |
Why?
|
| Cell Line | 1 | 1996 | 456 | 0.010 |
Why?
|
| Deoxyribonuclease HindIII | 1 | 1993 | 1 | 0.010 |
Why?
|
| Deoxyribonucleases, Type II Site-Specific | 1 | 1993 | 4 | 0.010 |
Why?
|
| Hydrolysis | 1 | 1993 | 39 | 0.010 |
Why?
|
| Oligonucleotide Probes | 1 | 1993 | 4 | 0.010 |
Why?
|
| Recombination, Genetic | 1 | 1993 | 21 | 0.010 |
Why?
|
| Tajikistan | 1 | 1992 | 1 | 0.010 |
Why?
|
| DNA, Single-Stranded | 1 | 1992 | 12 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1993 | 76 | 0.010 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1992 | 37 | 0.010 |
Why?
|
| Fetal Diseases | 1 | 1992 | 16 | 0.010 |
Why?
|
| Heterozygote | 1 | 1992 | 53 | 0.010 |
Why?
|
| Beta-Globulins | 1 | 1990 | 1 | 0.010 |
Why?
|
| Haploidy | 1 | 1990 | 1 | 0.010 |
Why?
|